Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kater AP"'
Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment- related imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::edcfbb63486e80d26627f3502ca9bb04
https://www.bib.irb.hr/1253909
https://www.bib.irb.hr/1253909
Autor:
Baliakas, P, Jeromin, S, Iskas, M, Puiggros, A, Plevova, K, Nguyen-Khac, F, Davis, Z, Rigolin, GM, Visentin, A, Xochelli, A, Delgado, J, Baran-Marszak, F, Stalika, E, Abrisqueta, P, Durechova, K, Papaioannou, G, Eclache, V, Dimou, M, Iliakis, T, Collado, R, Doubek, M, Calasanz, MJ, Ruiz-Xiville, N, Moreno, C, Jarosova, M, Leeksma, AC, Panayiotidis, P, Podgornik, H, Cymbalista, F, Anagnostopoulos, A, Trentin, L, Stavroyianni, N, Davi, F, Ghia, P, Kater, AP, Cuneo, A, Pospisilova, S, Espinet, B, Athanasiadou, A, Oscier, D, Haferlach, C, Stamatopoulos, K, ERIC European Res Initiative CLL
Publikováno v:
BLOOD
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Recent evidence suggests that complex karyotype (CK) defined by the presence of >= 3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::9f9f689ecd14b481ee08ad2c93add567
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2924
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2924
Autor:
Rawstron, AC, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, K-A, Liptrot, S, O'Brien, D, de Tute, RM, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, AP, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, JL, Stetler-Stevenson, M, Yuan, C, Broome, HE, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, CM, Emerson, R, Robins, HS, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, TJ, Wierda, WG, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P, CLL, ERIC European Res Initiative
Publikováno v:
Leukemia
Leukemia, vol 30, iss 4
Leukemia, 30(4), 929-936. Nature Publishing Group
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Leukemia, vol 30, iss 4
Leukemia, 30(4), 929-936. Nature Publishing Group
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223b87a88cadbba63e43e546bd4fa680
Autor:
Kersting, S, Levin, MD, Chamuleau, M, Daenen, SMGJ, Dompeling, E C, Doorduijn, Jeanette, van Gelder, M, Hoogendoorn, M, Kerst, JM, Nijland, M, Nijziel, MR, Posthuma, EFM, Raymakers, RAP, Schaafsma, MR, Silbermann, MH, Oudemans-van Straaten, HM, Veelken, JH, Vos, J M I, Wittebol, S, van Oers, MHJ, Kater, AP
Publikováno v:
Netherlands Journal of Medicine, 74(2), 68-74. Van Zuiden Communications
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::ed6adbdcb70145e06cb8e4ee3f05cd9e
https://pure.eur.nl/en/publications/1d753ad6-89bd-4c2a-b940-dfad43fdca3f
https://pure.eur.nl/en/publications/1d753ad6-89bd-4c2a-b940-dfad43fdca3f
Autor:
David Gonzalez, John G. Gribben, Emili Montserrat, Jitka Malčíková, Stephan Stilgenbauer, Hartmut Döhner, Davide Rossi, Arnon P. Kater, Šárka Pospíšilová, Thorsten Zenz, Florence Cymbalista, Paolo Ghia, Michael Hallek, M. H. J. Van Oers, Barbara Eichhorst, Peter Hillmen, Martin Trbušek
Publikováno v:
Leukemia. 26(7):1458-1461
Recent evidence suggests that - in addition to 17p deletion - TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data from retrospective analyses and prospective clinical trials show that similar to 5% of untreat